Pharma News

US House passes bill to repeal and replace Obamacare

  • Posted on: 5 May 2017
  • By: Shalini.Sharma

The US House of Representatives, controlled by the Republicans, passed a new version of the American Health Care Act to repeal and replace Obamacare, by a vote of 217 to 213. The Republican leaders of the house have blurred to gain sufficient support for the vote after adding a series of changes since an earlier version was taken from a vote in Parliament at the last minute of March.

Roche Diagnostics launch self-monitoring meter for patients on warfarin anticoagulant therapy

  • Posted on: 2 May 2017
  • By: PharmaTutor News

Roche Diagnostics UK and Ireland launches the next generation of INR patient self-monitoring meter for patients on warfarin anticoagulant therapy. The new CoaguChek INRange meter allows patients to send their results to their clinic via an App on their phone using wireless connectivity.

Takeda Announces FDA approval of ALUNBRIG (brigatinib)

  • Posted on: 2 May 2017
  • By: PharmaTutor News

Takeda Pharmaceutical Company Limited announced that ALUNBRIG™ (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under Accelerated Approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ALUNBRIG, which previously received Breakthrough Therapy Designation from the FDA, is a once-daily oral therapy that may be taken with or without food.

ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients

  • Posted on: 1 May 2017
  • By: PharmaTutor News

ProQR Therapeutics N.V. announced that the Company can start the Phase 1/2 trial for QR-110, named PQ-110-001, in Leber’s congenital amaurosis Type 10 (LCA 10) patients. QR-110 is a novel investigational RNA therapeutic targeting LCA 10 due to the p.Cys998X mutation, a severe genetic rare disease that causes children to lose sight in the first years of life. LCA 10 is one of the most prevalent forms of gene-related blindness in children worldwide and currently there are no therapies commercially available.